MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD, May 13, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences this month:
馬里蘭州羅克維爾，2024年5月13日（GLOBE NEWSWIRE）——專注於開發、製造和商業化用於治療癌症的創新單克隆抗體療法的生物製藥公司MacroGenics, Inc.（納斯達克股票代碼：MGNX）今天宣佈，該公司的管理層將參加本月的以下投資者會議：
-
- The Citizens JMP Life Sciences Conference (New York). MacroGenics' President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Tuesday, May 14, 2024, at 10:30 am ET. MacroGenics' management will also participate in one-on-one meetings.
- TD Cowen's 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA (Virtual). MacroGenics' President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Wednesday, May 29, 2024, at 12:30 pm ET.
-
- Citizens JMP 生命科學會議（紐約）。MacroGenics總裁兼首席執行官斯科特·科尼格醫學博士、博士將於美國東部時間2024年5月14日星期二上午10點30分參加爐邊談話。Macrogenics的管理層還將參加一對一的會議。
- TD Cowen的第五屆年度腫瘤學創新峯會：ASCO和EHA見解（虛擬）。MacroGenics總裁兼首席執行官斯科特·科尼格醫學博士、博士將於美國東部時間2024年5月29日星期三中午12點30分參加爐邊談話。
Webcasts of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain archived replays of these webcasts on its website for 30 days.
可以在Macrogenics網站投資者關係部分的 “活動與演講” 下訪問上述演講的網絡直播 http://ir.macrogenics.com/events.cfm。公司將在其網站上保留這些網絡廣播的存檔重播30天。
About MacroGenics, Inc.
關於 MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
MacroGenics（以下簡稱 “公司”）是一家生物製藥公司，專注於開發、製造和商業化用於治療癌症的基於單克隆抗體的創新療法。該公司主要從其專有的下一代抗體技術平台套件中生成候選產品線，這些平台適用於廣泛的治療領域。MacroGenics的技術平台和蛋白質工程專業知識相結合，使公司能夠開發出有前途的候選產品，並與全球製藥和生物技術公司進行多項戰略合作。欲了解更多信息，請訪問公司的網站 wwwmacrogenics.com。MacroGenics 和 MacroGenics 徽標是 MacroGenics, Inc. 的商標或註冊商標。
###
###
CONTACT: Jim Karrels, Senior Vice President, CFO 1-301-251-5172, info@macrogenics.com
聯繫人：吉姆·卡雷爾斯，高級副總裁，首席財務官 1-301-251-5172， info@macrogenics.com
Source: MacroGenics, Inc.
資料來源：MacroGenics, Inc.